Orbit Discovery Secures $12.6M to Accelerate Next-Gen Peptide Therapeutics Innovation

Orbit Discovery is excited to announce a major milestone in its journey towards revolutionizing drug discovery, having successfully raised $12,600,000 in its latest funding round. Founded in late 2015 as a spin-out from Oxford University based on the pioneering work of Professors Graham Ogg and Terry Rabbitts, Orbit Discovery has rapidly become a trailblazer in the development of innovative drug discovery platforms. At the core of this achievement is the company’s unique peptide display engine—a cutting-edge technology that enables the identification of novel, functional peptide therapeutic leads in biologically relevant contexts. This breakthrough platform is specifically designed to address cell-based targets, thereby allowing scientists to screen targets within their natural environment and to develop peptide, peptidomimetic, and small molecule therapeutics alongside bioconjugates for precise cell targeting and cargo delivery. The new funds will be primarily used to accelerate the development of the company’s robust pipeline of novel targets within its in-house programmes, while also expanding collaborative efforts across industry and academia. This strategic investment ensures that Orbit Discovery continues to drive forward research that has the potential to transform healthcare by delivering next-generation therapies. Emphasizing both scientific excellence and accessibility, Orbit Discovery aims to further democratize its revolutionary technology, ultimately paving the way for innovative treatments that cater to unmet clinical needs. With this fresh infusion of capital, the company is well-prepared to expand its research capabilities and solidify its leadership in the field of peptide-based drug discovery.